<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37272468</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-6834</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Infection control and hospital epidemiology</Title><ISOAbbreviation>Infect Control Hosp Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020-2022.</ArticleTitle><Pagination><StartPage>1972</StartPage><EndPage>1978</EndPage><MedlinePgn>1972-1978</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/ice.2023.95</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine risk factors for the development of long coronavirus disease 2019 (COVID-19) in healthcare personnel (HCP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a case-control study among HCP who had confirmed symptomatic COVID-19 working in a Brazilian healthcare system between March 1, 2020, and July 15, 2022. Cases were defined as those having long COVID according to the Centers for Disease Control and Prevention definition. Controls were defined as HCP who had documented COVID-19 but did not develop long COVID. Multiple logistic regression was used to assess the association between exposure variables and long COVID during 180 days of follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 7,051 HCP diagnosed with COVID-19, 1,933 (27.4%) who developed long COVID were compared to 5,118 (72.6%) who did not. The majority of those with long COVID (51.8%) had 3 or more symptoms. Factors associated with the development of long COVID were female sex (OR, 1.21; 95% CI, 1.05-1.39), age (OR, 1.01; 95% CI, 1.00-1.02), and 2 or more SARS-CoV-2 infections (OR, 1.27; 95% CI, 1.07-1.50). Those infected with the SARS-CoV-2 &#x3b4; (delta) variant (OR, 0.30; 95% CI, 0.17-0.50) or the SARS-CoV-2 o (omicron) variant (OR, 0.49; 95% CI, 0.30-0.78), and those receiving 4 COVID-19 vaccine doses prior to infection (OR, 0.05; 95% CI, 0.01-0.19) were significantly less likely to develop long COVID.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long COVID can be prevalent among HCP. Acquiring &gt;1 SARS-CoV-2 infection was a major risk factor for long COVID, while maintenance of immunity via vaccination was highly protective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Alexandre R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-7577-7688</Identifier><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampaio</LastName><ForeName>Vanderson Souza</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Instituto Todos Pela Sa&#xfa;de, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozahata</LastName><ForeName>Mina Cintho</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-1272-2380</Identifier><AffiliationInfo><Affiliation>Instituto Todos Pela Sa&#xfa;de, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto Todos Pela Sa&#xfa;de, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brito</LastName><ForeName>Anderson F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Instituto Todos Pela Sa&#xfa;de, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bragatte</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto Todos Pela Sa&#xfa;de, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalil</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto Todos Pela Sa&#xfa;de, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miraglia</LastName><ForeName>Jo&#xe3;o Luiz</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-4788-6254</Identifier><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malheiro</LastName><ForeName>Daniel Tavares</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guozhang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teich</LastName><ForeName>Vanessa Damazio</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Victor</LastName><ForeName>Elivane da Silva</ForeName><Initials>EDS</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinho</LastName><ForeName>Jo&#xe3;o Renato Rebello</ForeName><Initials>JRR</Initials><Identifier Source="ORCID">0000-0003-3999-0489</Identifier><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cypriano</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Laura Wanderly</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polonio</LastName><ForeName>Miria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Solange Miranda</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricardo</LastName><ForeName>Vict&#xf3;ria Catharina Volpe</ForeName><Initials>VCV</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maezato</LastName><ForeName>Aline Miho</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callado</LastName><ForeName>Gustavo Yano</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0001-6694-6569</Identifier><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schettino</LastName><ForeName>Guilherme de Paula Pinto</ForeName><Initials>GPP</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Ketti Gleyzer</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>R&#xfa;bia Anita Ferraz</ForeName><Initials>RAF</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malta</LastName><ForeName>Fernanda de Mello</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0001-8887-5060</Identifier><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amgarten</LastName><ForeName>Deyvid</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boechat</LastName><ForeName>Ana Laura</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4751-6859</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perencevich</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmond</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>West Virginia University School of Medicine, Morgantown, West Virginia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Luiz Vicente</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Infect Control Hosp Epidemiol</MedlineTA><NlmUniqueID>8804099</NlmUniqueID><ISSNLinking>0899-823X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>V.S.S., M.C.O., M.B., A.B., and J.K. are researchers at Instituto Todos pela Sa&#xfa;de (ITpS), which funded this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>2</Day><Hour>10</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37272468</ArticleId><ArticleId IdType="pmc">PMC10755155</ArticleId><ArticleId IdType="doi">10.1017/ice.2023.95</ArticleId><ArticleId IdType="pii">S0899823X23000958</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Long COVID or post&#x2013;COVID conditions. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Published 2022. Accessed May 20, 2022.</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022;226:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 2022;114:252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19&#x2013;related symptoms, hospital admissions, and mortality in older adults in England: test negative case&#x2013;control study. BMJ Clin Res 2021;373:n1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 2021;397:72&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832220</ArticleId><ArticleId IdType="pubmed">33306990</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita DM, Dos Santos Soares G, Sartori GP, Henrique da Silva Nali L. COVID-19 and Influenza coinfection: the rise of omicron and H3N2 in Brazil&#x2014;2022. Trav Med Infect Dis 2022;46:102262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8759102</ArticleId><ArticleId IdType="pubmed">35038569</ArticleId></ArticleIdList></Reference><Reference><Citation>Brizzi A, Whittaker C, Servo LMS, et al. Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. Nat Med 2022;28:1476&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307484</ArticleId><ArticleId IdType="pubmed">35538260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad FB AR, Cisewski JA, Sutton PD. Identification of deaths with post-acute sequelae of COVID-19 from death certificate literal text: United States, January 1, 2020&#x2013;June 30, 2022. NCHS Vital Statistics Rapid Release 2022;25.</Citation></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Med 2022;28:2398&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID&#x2014;mechanisms, risk factors, and management. BMJ Clin Res 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in nonhospitalized adults. Nature Med 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotrin P, Moura W, Gambardela-Tkacz CM, et al. Healthcare workers in Brazil during the COVID-19 pandemic: a cross-sectional online survey. Inquiry 2020;57:46958020963711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550936</ArticleId><ArticleId IdType="pubmed">33034257</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria de Moura Villela E, Rodrigues da Cunha I, Nelson Siewe Fodjo J, Obimpeh M, Colebunders R, Van Hees S. Impact of COVID-19 on healthcare workers in Brazil between August and November 2020: a cross-sectional survey. Int J Environ Res Public Health 2021;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8296453</ArticleId><ArticleId IdType="pubmed">34204195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumtaz A, Sheikh AAE, Khan AM, et al. COVID-19 vaccine and long COVID: a scoping review. Life (Basel) 2022;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9324565</ArticleId><ArticleId IdType="pubmed">35888154</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in healthcare workers. JAMA 2022;328:676&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med 2021;385:1393&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar R, Garg I, Pal S, Kottewar S, Sheikh AB. COVID-19 vaccine booster: to boost or not to boost. Infect Dis Rep 2021;13:924&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628913</ArticleId><ArticleId IdType="pubmed">34842753</ArticleId></ArticleIdList></Reference><Reference><Citation>Greninger AL, Naccache SN, Federman S, et al. Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis. Genome Med 2015;7:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587849</ArticleId><ArticleId IdType="pubmed">26416663</ArticleId></ArticleIdList></Reference><Reference><Citation>
What is COVID-19 reinfection? Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html. Published 2023. Accessed March 22, 2023.</Citation></Reference><Reference><Citation>Elbe S, Data Buckland-Merrett G., disease and diplomacy: GISAID&#x2019;s innovative contribution to global health. Glob Challenges (Hoboken) 2017;1:33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607375</ArticleId><ArticleId IdType="pubmed">31565258</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021;4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022;5:e2238804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022;10:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med 2022;10:761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Guida F, Polesel J, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2021;11:1685&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9291310</ArticleId><ArticleId IdType="pubmed">34109765</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. Nat Commun 2022;13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ Clin Res Ed 2021;372:n579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941603</ArticleId><ArticleId IdType="pubmed">33687922</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022;386:1532&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against COVID-19. N Engl J Med 2022;387:1279&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 2022;399:1303&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Cancela-Cilleruelo I, Rodr&#xed;guez-Jim&#xe9;nez J, et al. Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with Wuhan, alpha or delta SARS-CoV-2 variant. Pathogens 2022;11:725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022;399:2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Rodr&#xed;guez-Jim&#xe9;nez J, Cancela-Cilleruelo I, et al. Post&#x2013;COVID-19 symptoms 2 years after SARS-CoV-2 Infection among hospitalized vs nonhospitalized patients. JAMA Netw Open 2022;5:e2242106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667330</ArticleId><ArticleId IdType="pubmed">36378309</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Kobayashi T, Suzuki H, et al. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post&#x2013;COVID-19 conditions: a systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol 2022;2:e192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="pubmed">36505947</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hare AM, Vig EK, Iwashyna TJ, et al. Complexity and challenges of the clinical diagnosis and management of long COVID. JAMA Netw Open 2022;5:e2240332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9634500</ArticleId><ArticleId IdType="pubmed">36326761</ArticleId></ArticleIdList></Reference><Reference><Citation>
Antibody Testing is not currently recommended to assess immunity after COVID-19 vaccination: FDA Safety Communication. US Food and Drug Administration website. https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety. Accessed May 23, 2023.</Citation></Reference><Reference><Citation>Marra AR, Miraglia JL, Malheiros DT, et al. Effectiveness of heterologous COVID-19 vaccine booster dosing in Brazilian healthcare workers, 2021. Clin Infect Dis 2023;76:e360&#x2013;e366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213833</ArticleId><ArticleId IdType="pubmed">35639918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>